•  
  •  
  •  
  •  

2025-10-10 04:21:44

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Brightcom Group and Project DYNAMO Sign MoU to Advance Disaster Preparedness and Civilian Resilience Using Defence-Grade Systems
  • LGT India Journez recognized Inbound Tour Operator by Ministry of Tourism
  • NPST Goes Live with NPCI's UPI Services at GFF 2025
  • AccelerateBS India Ltd signs non-binding MOU to acquire company in USA
  • Cosmo First achieves globally recognised Information Security Management System Certificate - IS0/IEC 27001:2022

Keywords Selected:  Pharmaceuticals

Research

  • Kotak Institutional Equities - Pharmaceuticals: IPM pulse - gaining momentum
  • Company Update - P&G Health - ICICI Direct
  • Quant Pick - Cadila Healthcare - ICICI Direct
  • Q2FY22 Result Update - Syngene International - ICICI Direct
  • Syngene International Ltd - Lack of near term triggers - YES Securities
  • Syngene International Ltd - Lower gross margin lead to EBIDTA miss - YES Securities

IPO News

  • Accretion Pharmaceuticals' IPO Opens for subscription today, Price Band set at ₹96-101 per Share
  • Accretion Pharmaceuticals Ltd IPO to open for subscription on May 14, 2025
  • Senores Pharmaceuticals IPO subscribed 13.93 times on Day 2
  • Senores Pharmaceuticals IPO fully subscribed on Day 1
  • Senores Pharmaceuticals gets Sebi nod for IPO

Stock Report

  • Legal update regarding Risdiplam - Commercial Appellate Division of the Hon'ble Delhi High Court Dismissed Appeal
  • Fredun Pharmaceuticals Acquires Wagr.ai
  • Lupin unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable Platform
  • Shukra Pharmaceuticals Ltd receives order from Meril Healthcare Pvt Ltd
  • Sai Life Sciences, Agility Life Sciences, and Centrix Pharma announce an 'Integrated CMC Partnership' to accelerate drug development for innovators
  • Concord Biotech Ltd completes NAFDAC inspection successfully
  • Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg
  • Zydus receives final approval from USFDA for Deflazacort oral suspension, 22.75 mg/mL
  • Shilpa Medicare Ltd allots 9,77,90,908 Bonus Equity shares
  • FDC Ltd receives USFDA approval for ANDA Pilocarpine Hydrochloride Ophthalmic Solutions
  • AstraZeneca Pharma India Ltd receives sale and distribution approval from CDSCO for Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder
  • Lupin Launches Liraglutide Injection in the United States
  • Synbiotics Ltd's Amphotericin B Manufacturing Facility receives USFDA approval
  • Sentynl Therapeutics updates on its NDA for CUTX-101
  • Veerhealth Care Limited receives order for Hair Care and Oral Care products
  • Lupin Launches Rivaroxaban for Oral Suspension in the United States
  • Wockhardt Submits New Drug Application to U.S. FDA for Zidebactam-Cefepime for Treatment of Serious GramNegative Infections
  • Lupin receives approval from U.S. FDA for Rivaroxaban for Oral Suspension
  • Syschem India Ltd announces expansion, to set up new production unit
  • Lupin Strengthens its Global Specialty Ophthalmology Business with acquisition of VISUfarma from GHO Capital
  • Haleos Labs Limited successfully completes ANVISA audit at Unit-1
  • THE LANCET Regional Health publishes Pivotal Phase 3 Clinical Study on Miqnaf®
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Paroxetine Extended Release Tablets USP, 25 mg and 37.5 mg.
  • Glenmark Strengthens Oncology Portfolio with Hengrui's HER2 Targeting ADC For Multiple Regions

Industry News

  • NYSE Listed Amneal Pharmaceuticals begins Commercial Operations in India

Latest Post

  • Brightcom Group and Project DYNAMO Sign MoU to Advance Disaster Preparedness and Civilian Resilience Using Defence-Grade Systems
  • LGT India Journez recognized Inbound Tour Operator by Ministry of Tourism
  • NPST Goes Live with NPCI's UPI Services at GFF 2025
  • AccelerateBS India Ltd signs non-binding MOU to acquire company in USA
  • Cosmo First achieves globally recognised Information Security Management System Certificate - IS0/IEC 27001:2022


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024